Skip to main content
Fig. 3 | BMC Neurology

Fig. 3

From: Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer’s disease polygenic risk score

Fig. 3

Effects of APOE genotype, AD-PRS and amyloid-β status on changes in memory composite scores. Model-based estimation of longitudinal changes in memory composite score, based on APOE genotype (A), polygenic risk score (PRS) for Alzheimer’s Disease (B) and amyloid-β status (C). Neuropsychological tests were z-transformed and averaged for the composite memory score. APOE genotype dosage variable used as factor for plots: ɛ2 heterozygous/homozygous (APOE ɛ2ɛ2:ɛ2ɛ3), ɛ3ɛ3 (APOE ɛ3ɛ3), ɛ4 heterozygous (APOE ɛ2ɛ4:ɛ3ɛ4) and ɛ4 homozygous (APOE ɛ4ɛ4). AD-PRS depicted in tertiles. Amyloid-β status was based on visual read [18F]flutemetamol PET standardized uptake value images. Fixed-effect covariates were baseline age, sex, education, center and population substructure. For statistics see Table 2. AD = Alzheimer’s disease; APOE = apolipoprotein E; PET = positron emission tomography; PRS = polygenic risk score

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us